Lam Research (LRCX) moved up to the #59 spot in ETF Channel's ranking of analyst recommendations among S&P 500 components, overtaking Regeneron Pharmaceuticals (REGN). The piece is primarily a ranking update and does not include earnings, guidance, or other fundamental changes. Market impact should be limited, with the main relevance being to analyst sentiment and relative positioning.
Lam Research (LRCX) moved up to the #59 spot in ETF Channel's ranking of analyst recommendations among S&P 500 components, overtaking Regeneron Pharmaceuticals (REGN). The piece is primarily a ranking update and does not include earnings, guidance, or other fundamental changes. Market impact should be limited, with the main relevance being to analyst sentiment and relative positioning.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
